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CLLU1, DMD, GLO1, HCSL1, KIAA0977, LPL, MGC9913, PCDH9,
PEG10, SEPT10, TCF7, TCL1, TP53, VIM, ZAP70, ZNF2) were deter-
mined by real-time quantitative RT-PCR (RQ-PCR) in CD19-purified as
well as unpurified patients samples. Their predictive value regarding
individual genetic subgroups, an integrated genetic risk model, treat-
ment free (TFS) and overall survival times (OS) was investigated in 151
CD19 purified patients samples including multivariate analyses. In a
subset of 55 cases ZAP-70 expression was determined by FACS for com-
parison with RQ-PCR data. Results. The strongest association with the
VH mutation status was observed for LPL (correct prediction of 84% of
cases) and ZAP70 (84%), followed by TCF7 (74%), a marker being over-
expressed in VH mutated CLL. Additional significant associations were
observed between the 11q- subgroup and ATM (downregulation), and
between the 17p- subgroup and TCL1, TCF7, ZNF2, and ADAM29 (all
downregulated). Patients at genetic risk (VH unmutated or V3-21 usage
or 11q- or 17p-) were best assigned by ZAP70, whereby a determination
by RQ-PCR yielded better results compared to the FACS method. When
assessing a hierarchical risk model integrating the relevant genetic sub-
groups (risk 17p- > 11q- > VH unmutated or V3-21 usage > VH mutat-
ed) high misclassification rates occurred with any individual marker
(42% for ZAP70), which was mainly due to the impossibility of sepa-
rating cases with 11q- and 17p- from VH unmutated cases without these
abnormalities. This was improved using a marker combination (misclas-
sification rate 30% for a combination of LPL, TCF7, ZAP70, ZNF2, and
ATM). Still, a discrimination of 11q- or 17p- from VH unmutated patients
without these abnormalities was achieved in only approx. 50% of 11q-
and 17p- cases. In multivariate analyses including all candidate genes, LPL
was the strongest OS predictor, whereas TFS was best predicted by
ZAP70 and TCF7. When genetic factors were included in multivariate OS
and TFS analyses, the surrogate markers lost their independent prog-
nostic significance. Conclusions. Screening for patients at genetic risk can
be performed using the individual markers ZAP70 or LPL. Usage of a
marker combination reduces misclassifications especially regarding the
highest risk groups 11q- and 17p-. However, a reliable distinction of
these risk groups is not achieved and the prognostic impact of the sur-
rogate markers remains inferior compared to the established genetic fac-
tors.
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Background. Distinct genetic abnormalities such as TP53 deletion at
17p13.1 have been identified as having an adverse prognostic relevance
in B-cell chronic lymphocytic leukemia (B-CLL). Conventional cytoge-
netic studies have shown that TP53 deletion in B-CLL is associated pre-
dominantly with 17p loss (17p-) resulting from different complex chro-
mosomal rearrangements such as unbalanced translocations or isochro-
mosome 17q formation. Aims. The purpose of this study was to charac-
terize a deletion-mapping of chromosome 17p in a subset of 17p- B-
CLLs using genome-wide DNA profiling and Fluorescence in-situ
hybridization (FISH) analyses. Additionally, gene expression profiling
analysis was performed to identify specific transcriptional patterns or
altered molecular pathways associated with 17p aberrations, which may
have biological and clinical relevance in 17p- B-CLL. Methods. A panel of
71 untreated Binet A B-CLLs (18 of which carrying a TP53 monoallelic
deletion) was characterized for the most recurrent genomic aberrations
(trisomy 12 and deletions of 13q14, 11q22.3 and 17p13) and for the
major prognostic markers. The genomic profile of chromosome 17p was
investigated with GeneChip® Human Mapping 50K Xba 240 arrays in
12/18 17p- B-CLLs. Inferred copy numbers were derived from a Hidden
Markov Model (HMM) based algorithm implemented in CNAT 4.0.1
software (Affymetrix). FISH probes covering a region of approximately
6 Mb in 17p11.2-p12 was selected to validate the array results. The tran-
scriptional profiles of the 60 B-CLLs (7 carrying 17p-) have been gener-
ated on Affymetrix GeneChip® U133A arrays. The identified transcrip-
tional fingerprints of the 17p- cases was validated on an independent
dataset of 100 B-CLL cases (Haslinger et al., 2004) using a Multi-class Pre-
diction Analysis. Polymerase chain reaction was used to define the muta-
tional status of the TP53. Results. Genome-wide DNA analysis of TP53
-deleted samples showed 17p loss in 11/12 cases, with distinct deletion
patterns scattered along the 17p11.2-p12 region. FISH analysis confirmed
these findings and revealed 17p loss in a small fraction of leukemic cells
in the remaining TP53 -deleted case. In addition, FISH indicated 17p loss
in the 6/18 cases not investigated by SNP. Mutations in exons 5 to 9 of
the remaining TP53 allele were found in 9/12 deleted samples. Gene
expression profiling of 60 B-CLLs, including 7 patients with 17p loss,
identified 40 differentially expressed genes in 17p- vs 17p normal sam-
ples, 35 of which were down-regulated in 17p- tumors: the majority
(30/35) of these transcripts, including putative tumor suppressor genes
(GABARAP, GPS2 and OVCA1) mapped to 17p, indicating a remark-
able gene dosage effect. Conclusions. Our study confirms and extends
previous observations indicating that TP53 deletion in B-CLL patients is
associated with the loss of chromosome 17p. Gene expression profiling
showed that chromosome 17p loss is associated with significant down-
regulation of genes located on 17p, indicating a gene-dosage effect. The
potential coordinated loss of tumor suppressor genes on 17p other than
TP53 , may represent an important mechanism for the negative clinical
outcome associated with this lesion in B-CLL and warrants further inves-
tigation.
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Background. B-cell chronic lymphocytic leukemia (B-CLL) is a geneti-
cally heterogeneous disease with a high variable clinical course. Trisomy
12 (+12) is frequently associated with the disease (approximately 20%)
and it has been reported to be correlated with an intermediate progno-
sis. Despite the recent remarkable progresses in the understanding the
molecular pathogenesis of B-CLL, the biological significance of trisomy
12 remains to be fully elucidated. Aims. To identify signalling pathways
and additional lesions associated with tumorigenesis in +12 B-CLLs.
Methods. A panel of 80 Binet A untreated B-CLLs including 18 patients
with trisomy 12 was investigated. This series was characterized for the
most recurrent genomic aberrations (deletions of 13q14, 11q22.3 and
17p13) and for the major prognostic markers. Gene expression profiles
were generated on Affymetrix GeneChip® U133A arrays. The identified
transcriptional fingerprint of +12 was generated and then validated on
an independent dataset of B-CLL cases (Haslinger et al., 2004) by a Mul-
ti -class Prediction Analysis. Furthermore, genome-wide profiling data
were generated by means of Affymetrix GeneChip® Human Mapping
250K Nsp SNP arrays in a subset of 45/80 B-CLLs including 9 patients
with +12. Inferred copy numbers were derived from a Hidden Markov
Model (HMM) based algorithm implemented in CNAT 4.0.1 software
(Affymetrix). Results. The transcriptional analysis revealed 140 genes as
the best classifier for the +12 B-CLLs. 92 out of the 118 genes up-regu-
lated in +12 patients mapped on chromosome 12, most of which (86%)
on the long arm. The remaining 26 genes and the 22 genes down-regu-
lated in +12 samples showed different chromosomal localizations. The
transcriptional fingerprint validation on an independent cohort of 100 B-
CLL patients showed a global classification rate of 92.5%. A functional
analysis of the deregulated genes revealed the involvement in transcrip-
tional regulation, DNA, mRNA and protein metabolism. Many genes
(ANAPC5, CCT2, CCT4, CDK2AP1, CDKN1B, CHFR, MCRS1, PCTK2)
were also related to regulation of cell-cycle, cell death (ATXN1, CD63,
DNM1L, DYRK2, HRK, OPTN, TEGT) and immune response (CKLF,
CD58, CTLA4, HDAC9, IL21R) as well as to different cellular metabol-
ic processes (AMPD3, CS, LDHB, NUDT4). Consistent with FISH data,
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genome-wide DNA analysis showed that +12 is never found to be asso-
ciated with the other most recurrent aberrations of B-CLL. Moreover,
SNPs analysis identified, among the +12 patients, other recurrent copy
number variations, such as gains of 14q32, 15q11, 17q21 and losses of
11p15, 14q11, 14q32 and 15q11: however, this correlation did not reach
a statistically significant level. Conclusions. Trisomy 12 appears to affect
gene expression in B-CLL not only by a dosage effect but also by influ-
encing the expression of genes located on different chromosomes lead-
ing to the deregulation of multiple cellular functions. None of the copy
number alterations identified by SNP genomic analysis appeared to be
tightly correlated with +12.
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CLL patients with 17p deletion have a dismal prognosis after treat-
ment. The exact prognostic role of TP53 mutations in the absence of 17p
deletion and any differential impact of the mutation in cases with 17p
deletion (vs sole deletion) is currently unclear. Aims. To assess the inci-
dence, profile and prognostic impact of TP53 mutations as assessed by
sensitive DHPLC followed by direct sequencing in a well characterized
and homogeneous patient population from a prospective trial (CLL4 tri-
al GCLLSG). Methods. We studied 342 of 375 CLL4 trial patients with
available material. The population is well characterized and detailed
genetic characteristics are available (FISH, VH-Status). We used DHPLC
to detect TP53 mutations in the coding exons (2-11). Aberrant profiles
were confirmed by sequencing including the use of fragment collection
in cases with low grade mutations. Results. We found an overall incidence
of TP53 mutations of 8.2 % (28/342 patients). The mutations were exclu-
sively located in the DNA binding domain. We observed 2 splice site
mutations, 3 deletions, 2 insertions but the majority of mutations were
missense mutations in exons 5-8. Two patients had 2 different muta-
tions. Fourteen of 16 patients with 17p deletions also had a TP53 muta-
tion (87.5 %). Interestingly, both patients with a 17p deletion where no
TP53 mutation was identified, showed a low proportion of 17p- cells
(19-21%) suggesting that detection limits of the technique might explain
this finding. We found TP53 mutations in the absence of 17p deletions
in 4.3% (14/326). The proportion of mutated allele in cases without 17p
deletion ranged from 10 to 90 percent. In two patients with follow-up
samples we found evidence of clonal evolution at the time of relapse.
The genetic profile of cases with TP53 mutation showed a high inci-
dence of 17p deletions (13/28 cases), but also included cases with 11q
deletion 3/28, 13 deletion as the sole abnormality (5/28) and normal
karyotype (4/28). The majority of cases with TP53 mutations had an
unmutated VH status (n=21)(75%), while 6 of 28 had a mutated VH
status (V3-21: n=1). Correlation with baseline parameters and clinical
outcome is currently being performed and will be presented. Conclu-
sions. In this first line treatment trial population, TP53 mutations with-
out 17p deletion occurred in 4.3% (14/326) of patients and the majori-
ty of cases with 17p deletion also have TP53 mutations. The demonstra-
tion of clonal evolution in cases with TP53 mutation without 17p dele-
tion after F-based therapy points to the biological and clinical signifi-
cance of TP53 mutations in CLL. 
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Background and Aims. Screening for gene copy-number alterations
(CNAs) has improved by applying genome-wide microarrays, where
SNP-arrays also allow analysis of loss-of-heterozygozity (LOH). Few
comparative studies of high-resolution platforms have thus far been per-
formed and there is a current need to compare platforms in order to
understand the pros and cons with the differently designed arrays. Here
we investigated chronic lymphocytic leukemia (CLL) samples by apply-
ing four differently designed microarrays for evaluation of: 1) baseline
variation and ratio response to FISH-validated genomic aberrations, 2)
detection of known recurrent and novel CNAs and concordance
between platforms, and 3) detection of LOH with the Illumina and
Affymetrix SNP-arrays. Materials and Methods. We screened 10 CLL sam-
ples using four different high-resolution platforms: BAC-arrays (32K),
oligonucleotide-arrays (185K, Agilent), and two SNP-arrays (250K,
Affymetrix and 317K, Illumina). Baseline variation and copy-number
ratio response was calculated on normalized array-data. Analysis of
CNAs and LOH was performed applying the Bio Array Software Envi-
ronment (BASE) and dChip software, respectively. Results. Evaluation of
baseline variation and copy-number ratio response showed the best per-
formance for the Agilent platform and confirmed the robustness of BAC-
arrays. Accordingly, these platforms demonstrated a higher degree of
platform-specific CNAs. The SNP-arrays displayed higher technical vari-
ation, although this was compensated by high density of elements.
Cross-platform comparison revealed 29 concordantly detected CNAs,
including FISH validated known recurrent alterations, which confirmed
that all platforms are powerful tools when screening for large aberra-
tions. However, detection of 32 additional regions present in 2-3 plat-
forms illustrated a discrepancy in detection of small CNAs, which often
involved reported copy-number variations. LOH-analysis using dChip
revealed concordance of mainly large regions, but showed numerous,
small non-overlapping regions and LOH escaping detection. Affymetrix
detected a higher degree of CNAs compared to Illumina, while the lat-
ter showed a lower noise level and higher detection rate in the LOH
analysis. Conclusions. Usage of high resolution microarrays will improve
the possibility to detect new recurrent microevents in CLL leading to
identification of new important subgroups potentially refining the prog-
nostic hierarchy established by FISH. If only copy-number data is pre-
ferred, oligonucleotide-arrays such as Agilent provide a high sensitivity
of this type of analysis. If LOH-analysis is desirable, SNP-arrays are the
preferred choice but, parallel improvement of analysis tools is required
for an in-depth analysis of allelic imbalances. 
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